MarketPeel
Insider Trading Intelligence
MS

Malcolm Salter

CCCC
DIRECTOR · C4 THERAPEUTICS, INC. · CIK 0001825124
FILING MIX · LIFETIME55%/45%
BUYS
12
SELLS
10
TOTAL VALUE
$318.7K
COMPANIES
1
ACTIVE SINCE
Oct 2020
HOLDINGS NOW
32,500
AVG SELL PX
$39.70
TRADE KIND
SHOWING 22 / 22
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
9 backtested trades · 8 horizons
Forward-return performance of every backtestable P/S trade by Malcolm Salter, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d9+33.33%-0.66%+1.62%-2.27%-0.09%
14d9+33.33%+1.43%+1.57%-0.14%-0.86%
30d9+55.56%-3.08%+1.69%-4.76%-8.69%
60d9+55.56%-3.95%+3.51%-7.45%-2.40%
90d9+66.67%-8.08%+3.73%-11.81%-7.83%
180d9+88.89%-37.26%+2.99%-40.25%-44.55%
1y9+100.00%-62.51%-6.23%-56.28%-65.48%
2y9+88.89%-89.65%+5.34%-94.98%-95.50%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CCCC · 32,500 shares · as of Jun 20, 2024
08,12516,25024,37532,5002021202220232024SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
FLOW · 12 buys / 10 sellsCOVERAGE · 15 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
32,50032,500Jun 20, 2024Jun 21, 2024View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
26,00026,000Jun 15, 2023Jun 16, 2023View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
23,50023,500Jun 22, 2022Jun 23, 2022View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
428$31.58$13.5K11,380Jan 4, 2022Jan 18, 2022View →
CCCC
C4 THERAPEUTICS, INC.
SALE
755$30.25$22.8K10,952Dec 17, 2021Dec 17, 2021View →
CCCC
C4 THERAPEUTICS, INC.
SALE
755$40.11$30.3K11,707Nov 19, 2021Nov 19, 2021View →
CCCC
C4 THERAPEUTICS, INC.
SALE
755$44.94$33.9K12,462Oct 15, 2021Oct 15, 2021View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
300$44.99$13.5K13,217Oct 4, 2021Oct 5, 2021View →
CCCC
C4 THERAPEUTICS, INC.
SALE
755$49.89$37.7K12,917Sep 17, 2021Sep 21, 2021View →
CCCC
C4 THERAPEUTICS, INC.
SALE
755$40.73$30.8K13,672Aug 20, 2021Aug 24, 2021View →
CCCC
C4 THERAPEUTICS, INC.
SALE
755$37.37$28.2K14,427Jul 16, 2021Jul 19, 2021View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
339$39.72$13.5K15,182Jul 2, 2021Jul 7, 2021View →
CCCC
C4 THERAPEUTICS, INC.
SALE
755$37.19$28.1K14,843Jun 18, 2021Jun 21, 2021View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
23,50023,500Jun 15, 2021Jun 17, 2021View →
CCCC
C4 THERAPEUTICS, INC.
SALE
755$37.12$28.0K15,598May 21, 2021May 24, 2021View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
359$37.51$13.5K16,353Apr 5, 2021Apr 6, 2021View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASE
2,82314,679Oct 6, 2020Oct 6, 2020View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASE
1,315$19.00$25.0K15,994Oct 6, 2020Oct 6, 2020View →
CCCC
C4 THERAPEUTICS, INC.
SALE
100,0000Oct 6, 2020Oct 6, 2020View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASE
11,85611,856Oct 6, 2020Oct 6, 2020View →
CCCC
C4 THERAPEUTICS, INC.
SALE
23,8090Oct 6, 2020Oct 6, 2020View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
17,78617,786Oct 1, 2020Oct 5, 2020View →
Other insiders · CCCC
Loading peer insiders…
About this filer
CIK 0001825124
ROLE
Director
PRIMARY
CCCC
COMPANIES
1
ACTIVE SINCE
Oct 2020
MARKETPEEL · /INSIDER/0001825124DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback